Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12
months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first
line treatment of metastatic colorectal cancer.
Phase:
Phase 3
Details
Lead Sponsor:
US Oncology Research
Collaborators:
Bristol-Myers Squibb Memorial Sloan Kettering Cancer Center Prologue Research International